Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 13.63

From 52W high−18.60%

Volume7.91M

Market capCNY 5.98B

P/E (TTM)91.8x

P/S (TTM)7.2x

Div yield0.54%

Key dataSep 18, 2026

Open

CNY 13.63

From 52W high

−18.60%

Volume

7.91M

Market cap

CNY 5.98B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

29.8x

P/E (TTM)

91.8x

RSI (14)

47.4

MomentumView details →

1D Return

+0.35%

YTD Return

−6.41%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

91.8x

EV/EBITDA

29.8x

EV/Sales

6.9x

P/S (TTM)

7.2x

P/B (TTM)

3.4x

ProfitabilityView details →

Gross Margin

57.51%

Net Margin

7.19%

EBITDA Margin

23.09%

ROE (TTM)

3.34%

ROA (TTM)

2.83%

Asset Turnover

0.39x

GrowthView details →

Revenue YoY

+1.87%

EPS YoY

−25.04%

FCF YoY

−71.41%

Revenue CAGR 3Y

+1.75%

EPS CAGR 3Y

−13.88%

EBITDA YoY

—

MomentumView details →

1D Return

+0.35%

YTD Return

−6.41%

1Y Return

−17.15%

RSI (14)

47.4

vs 50D SMA

−1.19%

vs 200D SMA

−2.04%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

4.68x

Quick Ratio

4.15x

Div Yield

0.54%

Div Rate

CNY 0.08

Div Growth 1Y

−11.76%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

800.05M

Net Income (TTM)

57.52M

Op. CF (TTM)

64.86M

Latest newsMore news →

Huasen Pharmaceutical completed the transfer of the China marketing authorization holder rights for buspirone hydrochloride tablets to Grand Pharma (Xi'an), with the NMPA approving the holder change from Huasen to Grand Pharma.2d ago

Huasen Pharmaceutical received a drug re-registration approval notice from the Chongqing Medical Products Administration for its injection of ethylenediamine diaceturate (0.2g, 0.4g), valid until February 20, 2032.27d ago

Similar companies

华新科技301265.SZ 春晖智控300943.SZ 泸天化000912.SZ 强力新材300429.SZ 炬华科技300360.SZ 箭牌家居001322.SZ Find similar companies →

Latest newsMore news →

Huasen Pharmaceutical completed the transfer of the China marketing authorization holder rights for buspirone hydrochloride tablets to Grand Pharma (Xi'an), with the NMPA approving the holder change from Huasen to Grand Pharma.2d ago Huasen Pharmaceutical received a drug re-registration approval notice from the Chongqing Medical Products Administration for its injection of ethylenediamine diaceturate (0.2g, 0.4g), valid until February 20, 2032.27d ago Huasen Pharmaceutical proposed a cash dividend of 0.35 yuan per 10 shares (tax included) based on total share capital of 418 million shares as of June 30, 2026, with no bonus shares or capital reserve conversion.31d ago